Helix Nanotechnologies

Helix Nanotechnologies

  • Founded: 2013
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: COVID-19
  • Drug types: VAC, INF, ONC
  • Lead product: Undisclosed
  • Product link: https://www.helixnano.com/
  • Funding: 10-100M



job board

Short description:

DNA Therapy

Drug notes:

Undisclosed RD oncology

Long description:

HelixNano is using artificial intelligence to treat genetic diseases. Messenger RNA (mRNA) contains information for a cell to make proteins, analogous to how technology finds information and delivers physical products. HelixNano is leveraging mRNA and improving its capabilities using first principles to enhance the speed and reduce the cost to develop therapies for genetic diseases. In particular, HelixNano is focusing on mRNA vaccines, recently pivoting from cancer therapies to creating better, second-generation, mutation-resistant Covid-19 vaccines. HelixNano has developed new vaccine technologies, which have a ‘zoom’ function and an ‘amplify’ function to rival current vaccines. HelixNano is also interested in creating topologically-applied vaccines that are stable at room temperature.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com